Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response.
Dragomir MP, Fuentes-Mattei E, Winkle M, Okubo K, Bayraktar R, Knutsen E, Qdaisat A, Chen M, Li Y, Shimizu M, Pang L, Liu K, Liu X, Anfossi S, Zhang H, Koch I, Tran AM, Mohapatra S, Ton A, Kaplan M, Anderson MW, Rothfuss SJ, Silasi R, Keshari RS, Ferracin M, Ivan C, Rodriguez-Aguayo C, Lopez-Berestein G, Georgescu C, Banerjee PP, Basar R, Li Z, Horst D, Vasilescu C, Bertilaccio MTS, Rezvani K, Lupu F, Yeung SC, Calin GA.
Dragomir MP, et al. Among authors: bertilaccio mts.
J Clin Invest. 2023 Jul 17;133(14):e158348. doi: 10.1172/JCI158348.
J Clin Invest. 2023.
PMID: 37261908
Free PMC article.